psoriasis

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targeting the CD4 molecule, effectively inhibiting T-cell receptor (TCR) signal transduction. It is used in research on rheumatoid arthritis, psoriasis, melanoma, cutaneous, and peripheral T-cell lymphoma [1].

Fletikumab (NNC0109-0012) is a monoclonal antibody that inhibits IL-20, primarily used in research on rheumatoid arthritis and psoriasis.

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production. Itolizumab can be used to study conditions such as psoriasis, rheumatoid arthritis (RA), and COVID-19 disease.

Anti-Human IL-17A is a fully human anti- interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis [1] .

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.

Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Prezalumab (AMG 557) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF, used for studying Sjogren's syndrome, cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis, and systemic lupus erythematosus (SLE).

Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody. Efalizumab has inhibitory effects on T cell activation, skin T cell transport, and T cell adhesion to keratinocytes, and can be used to study plaque psoriasis and psoriatic arthritis.

Imaprelimab (PRX-003) is a humanized IgG1 κ monoclonal antibody targeting melanoma cell adhesion molecule (MCAM), with antitumor activity and applications in studying inflammation, tumors, and psoriasis.

Neihulizumab (ALTB-168), an immune checkpoint agonistic antibody, targets and binds to human CD162 (PSGL-1), resulting in the downregulation of activated T-cells. It is utilized in research aimed at treating steroid-refractory acute graft-versus-host disease (SR-aGVHD), psoriasis, psoriatic arthritis, and ulcerative colitis [1].

Certolizumab is an antibody that helps relieve pain and swelling in arthritis. It works by blocking tumor necrosis factor (TNF). It is being studied for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease.

Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.

Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody targeting the p19 subunit of IL-23 with a Kd value of 136 pM, useful for studying psoriasis.

Orticumab (MLDL1278A) is an antibody that targets and inhibits oxidized or malondialdehyde-modified low-density lipoprotein (oxLDL), modulating autoimmune responses against oxLDL and showing potential to improve atherosclerosis in animal models. Additionally, Orticumab has been researched for its effectiveness in improving psoriasis [1] [2].

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.

Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1 Th17 and neutrophil pathways. Spesolimab can be used to study systemic pustular psoriasis, palmar and plantar impetigo (PPP), and atopic dermatitis.

Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody combining monovalent camelid-derived nanobodies targeting human interleukin (IL)-17A and IL-17F with human serum albumin VHHs, presenting it as a promising candidate for investigating plaque-type psoriasis treatments [1] [2].

Imsidolimab (ANB 019) is a humanized anti-IL-36R monoclonal antibody that inhibits IL-36 signaling and can be used to study systemic pustular psoriasis.

Alefacept (BG 9273), a fusion protein combining human lymphocyte function-associated antigen 3 with immunoglobulin 1, is utilized in the research of chronic plaque psoriasis [1].

Gumokimab (AK 111), a monoclonal antibody, targets IL-17A and is utilized in researching psoriasis and ankylosing spondylitis. It competitively inhibits the interaction between human IL-17A and its receptor, IL-17R.

Netakimab (BCD 085) is a humanized camel-derived monoclonal antibody targeting interleukin-17A, which can be used to study spondyloarthritis and plaque psoriasis.